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PEnd Points for Clinical Trials
in Acute Heart Failure Syndromes
Larry A. Allen, MD, MHS,* Adrian F. Hernandez, MD, MHS,† Christopher M. O’Connor, MD,†
G. Michael Felker, MD, MHS†
Aurora, Colorado; and Durham, North Carolina
Acute heart failure syndromes (AHFS) remain a major cause of morbidity and mortality, in part because the de-
velopment of new therapies for these disorders has been marked by frequent failure and little success. The het-
erogeneity of current approaches to AHFS drug development, particularly with regard to end points, remains a
major potential barrier to progress in the field. End points involving hemodynamic status, biomarkers, symp-
toms, hospital stay, end organ function, and mortality have all been employed either alone or in combination in
recent randomized clinical trials in AHFS. In this review, we will discuss the various end point domains from
both a clinical and a statistical perspective, summarize the wide variety of end points used in completed
and ongoing AHFS studies, and suggest steps for greater standardization of end points across AHFS
trials. (J Am Coll Cardiol 2009;53:2248–58) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.079i
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ccute heart failure syndromes (AHFS) are a family of
elated clinical entities characterized by new or worsening
igns or symptoms of heart failure leading to hospital stay.
aken together these disorders represent a major public
ealth problem, with a high degree of morbidity and a
apidly increasing prevalence (1). The adverse impact of
HFS on public health has been compounded by the
ailure to develop new and effective therapies for this
yndrome (2). Consequently, guideline recommendations
re sparse and largely driven by expert opinion (3,4).
espite significant advances in the care of patients with
table chronic heart failure, neither routine therapy for
atients with an episode of AHFS nor the subsequent
isk of death have changed significantly over the past 30
ears (5,6).
Why has there been so little progress in AHFS
herapy? Some of the explanation relates to patient
eterogeneity, as exemplified by the plural term “acute
eart failure syndromes.” This group of disorders in-
ludes patients with diverse presentations and pathophys-
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008, accepted December 23, 2008.ology, ranging from patients presenting suddenly with
ypertension and normal or near normal ejection fraction
o those with subacute presentations with advanced
ystolic dysfunction and low output states. Given that it
s unlikely that the same therapy would be efficacious in
uch varied patient populations, it is not surprising that
one-size-fits-all” attempts at developing new therapies
ave not met with success. Additionally, understanding
f underlying pathophysiologic mechanisms for AHFS
emains limited, and a framework for classification of
hese syndromes that incorporates both clinical and
athophysiologic differences is lacking. Finally, as we will
ocus on in this review, the methodology of clinical trials
n this area has remained poorly developed (7). There has
een little consensus in the research or regulatory com-
unity about a variety of aspects of clinical trial design in
HFS, resulting in a heterogeneous approach to drug
evelopment. Nowhere is this more apparent than in the
ack of agreement about the most appropriate end points
or clinical trials in AHFS. This is in sharp contrast to
he field of acute coronary syndromes, where there has
een broad consensus around the optimal efficacy end
oints for drug development since the thrombolytic era.
To advance the field of AHFS therapy, there is a need
o develop end point measures that encompass the
otality of potential therapeutic benefits in AHFS pa-
ients, including relief of symptoms, limiting length of
tay (LOS), decreasing repeat hospital stay, and prolong-
ng survival (Table 1). Greater standardization of end
oints across studies is needed for therapies to be easily
ompared and prioritized by clinicians and payers. Addi-
ionally, better validated surrogates for both efficacy and
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gents by reliably recognizing efficacy and safety issues
arlier in the development process. In this review, we will
ummarize end points used in previous and ongoing
HFS studies, describe the current regulatory environ-
ent for the approval of AHFS therapies, and discuss the
ey issues for the development of more robust end points
oving forward.
istory of Drug Development in AHFS
he evaluation and requirements for approval of AHFS
herapies have evolved significantly over the years. Initial
herapies for AHFS such as loop diuretic agents were
ccepted into practice largely on clinical experience in
ombination with pharmacokinetic and pharmacodynamic
ata. Milrinone was approved for AHFS by the U.S. Food
nd Drug Administration (FDA) in 1988 on the basis of its
emodynamic effects rather than on hard clinical end
oints. No additional agents were approved specifically for
se in AHFS until 2001, when nesiritide was granted
pproval by the FDA on the basis of short-term improve-
ents in both hemodynamic status and patient-reported
yspnea (8). Subsequently, there have been substantial
oncerns raised about the safety and efficacy of both mil-
inone (9) and nesiritide (10,11), which have led to in-
reased skepticism among both the clinical and the regula-
ory community about the end points on which to base
onclusions about drug efficacy and safety in AHFS. Since
he approval of nesiritide by the FDA in 2001, multiple
ovel therapies for AHFS have been tested in a variety of
linical trials, almost all of which used differing end points
nd which have resulted in a variety of interpretations
Table 2) (12). This uncertainty as to how to interpret the
vidence has led to AHFS therapies that are approved for
se in the U.S. but not in Europe (nesiritide) and,
onversely, drugs approved for use in Europe but not in
he U.S. (levosimendan). In the following text, we will
ummarize the advantages and disadvantages of various
ypes of end points that have been employed in clinical
rials of AHFS.
linical End Points
he value of a medical intervention is ultimately defined by
ow it affects the lives of patients. In general, the FDA has
andated that for a therapy to be approved it has to make
atients feel better and/or live longer (13). Consequently,
ivotal phase III trials of new therapies must demonstrate
linically relevant improvement in a clinical end point (as
istinct from a surrogate end point) to justify regulatory
pproval and clinical use.
ortality. Mortality is obviously an important end point in
ny clinical syndrome associated with substantial risk of
eath (such as AHFS). Mortality is objective and easy to
ssess, and its clinical relevance is self-evident. Controversy
emains about whether it is preferable to measure all-cause ar disease-specific mortality (14).
ll-cause mortality has the ad-
antage of a higher overall event
ate than disease-specific mortal-
ty as well as requiring no adju-
ication as to cause of death.
mportantly, however, all-cause
ortality will include events that
re unlikely to be responsive to
he therapy being tested, which will tend to diminish the
verall power of the analysis. Disease-specific event rates
elated to the specific mechanism of action of the therapy
e.g., sudden death in defibrillator trials) are much more
ikely to demonstrate a treatment effect, assuming that the
echanism of action of the therapy is reasonably well
nderstood. The use of disease-specific event rates generally
ecessitates the use of clinical event committees to adjudi-
ate cause of death. Although the process of adjudication
ight be challenging due to frequent comorbidity in
atients with heart failure or a lack of adequate docu-
entation of the event, the use of some form of clinical
vent adjudication has become standard in major cardio-
ascular trials (15). Recent data from the EVEREST
Efficacy of Vasopressin Antagonism in Heart Failure
utcome Study with Tolvaptan) trial found that most
ost-discharge deaths in patients with AHFS and systolic
ysfunction are cardiovascular in nature, suggesting that
se of disease-specific mortality might be less critical in
his population (16). Although data on cause of death in
atients with AHFS and normal ejection fraction are
acking, experience indicates that a higher proportion of
ortality in such patients might be noncardiac (17),
uggesting that disease-specific mortality might be a supe-
ior choice for AHFS studies focused on this population.
Despite its obvious appeal as a clinical end point, mor-
ality has not been used as the sole primary end point in any
arge clinical trials of AHFS therapies. Although AHFS is
highly morbid condition with in-hospital mortality rates
n the order of 4% to 7% and 30- to 60-day mortality rates
f 10% to 12% (3,4), trial designs have not targeted
ortality alone, because of the heterogeneity of the popu-
ation, the high prevalence of contributing comorbidities,
nd the recurrent failure of prior AHFS studies to positively
mpact survival. Additionally, it is uncertain the extent to
hich short-term AHFS therapies given during an index
ospital stay can impact post-discharge mortality. For a
hort-term AHFS therapy to affect mortality rates, it would
eed to: 1) significantly diminish in-hospital mortality;
) alter the fundamental natural history of the AHFS
yndrome in a way that leads to a reduction in subsequent
linical events; or 3) facilitate the introduction or up-
itration of chronic heart failure therapies known to improve
urvival. For example, acute reperfusion therapy for myo-
ardial infarction conveys a long-term survival benefit by
Abbreviations
and Acronyms
AHFS  acute heart failure
syndrome(s)
FDA  Food and Drug
Administration
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ith subsequent prevention of disease progression. Whether
uch a paradigm can be translated to AHFS therapies is
nknown, given that no over-arching fundamental mecha-
ism has been identified for this heterogeneous family of
isorders.
eart failure hospital stay. Much of the morbidity bur-
en of heart failure is the result of inpatient care, with
ver 1 million heart failure hospital stays annually in the
ategories of Potential End Points for Large Clinical Trials of AHFS
Table 1 Categories of Potential End Points for Large Clinical T
Category Specific End Points Ad
Objective clinical outcomes “Hard” measures
and mortality a
resource use
Mortality Ideal standard fo
objective, easi
on patients ov
LOS Important clinica
and societal re
Repeat hospital stay rates Important clinica
and societal re
Total days of hospital stay Important clinica
and societal re
Urgent care visits Frequent, clinical
Worsening heart failure/
need for rescue
therapy
Subjective clinical measures By definition rela
theoretically m
relevant
Dyspnea (VAS, Likert) Accepted
General well-being/global
status
Might represent m
experience tha
Health status (KCCQ,
MLHF, EQ-5D)
Validated in chron
Surrogates Typically objective
increase powe
Hemodynamic status
(PCWP)
Objective, correla
Weight loss Noninvasive, glob
status
BNP Objective, correla
Creatinine (GFR) Creatinine is a str
Composites Combined Might increase po
Ranked Might increase po
of the various
Cost An objective outc
societal impor
Safety Given track recor
therapies that
measures but
outcomes, me
events take on
HFS acute heart failure syndromes; BNP B-type natriuretic peptide; EQ-5D EuroQol 5-Dime
ity Cardiomyopathy Questionnaire; LOS length of stay; MLHFMinnesota Living with Heart Failu.S. alone (1). Hospital stay for AHFS is associated with mevere symptoms, diminished quality of life, worsened
ost-discharge prognosis, and substantial cost. For pa-
ients hospitalized with AHFS, both the LOS for the
ndex hospital stay (median of 6 days in the U.S.) and the
isk of repeat hospital stay (30% at 60 days) are substan-
ial (18,19). Thus, addressing the morbidity of AHFS by
reventing repeat hospital stay and limiting LOS is an
bvious therapeutic objective in AHFS.
Unlike mortality end points, hospital stay end points
rventions
f AHFS Interventions
ges Disadvantages
Approximate
Sample Size
uantify morbidity
nerally drive
Require large sample sizes; might not
necessarily capture short-term but
clinically relevant improvements in
patient QOL
Large
cy, highly
obtain accurately
-term follow-up
Number of patients needs to be large
and follow-up long; therapies that
improve QOL/symptoms but not
mortality are potentially valuable
103–104
ure for patient QOL
use
Highly variable among providers,
institutions, and countries; standards
for dischargability do not exist
102–103
ure for patient QOL
use
Follow-up period for event might be
affected by differences in LOS
102–103
ure for patient QOL
use
Includes LOS and is thus subject to the
same limitations
102–103
ningful Generally more difficult to capture;
wide variety of reasons for such
visits; generally of less significance
than a hospital stay
102–103
103–104
ow patients feel,
them clinically
Often highly subjective; generally
improve rapidly after admission
regardless of therapy
Lacks standardization; largely improves
regardless of intervention
102–103
spects of the AHFS
nea alone
Less standard and less defined than
dyspnea
102–103
rt failure Relatively complex and time-consuming
questionnaires
102–103
inuous variables Question clinical relevance
symptoms Has not correlated with important
clinical measures
101–102
sure of fluid Might not correlate highly with
symptoms or discharge; reliability
is questionable
101–102
symptoms Changes in BNP as effected by
different therapies have not been
validated to correlate with important
clinical measures
101–102
edictor of outcome Unknown whether interventions that
change creatinine correlate with
clinical outcomes
101–102
More difficult to interpret; least
important component often
drives result
102–104
raded importance
nents
Not commonly used, less-familiar;
statistically more complex
102–104
ith patient and Often requires assumptions about
multiple variables leading to wide
margins of confidence
102–103
me AHFS
ve short-term
worsen later
of longer-term
role
Assumes noninferiority statistical
properties that tend to greatly
increase required sample sizes;
as such most safety analyses are
ad hoc
104–105
health related quality of life descriptive system; GFR glomerular filtration rate; KCCQ Kansas
tionnaire; PCWP post-capillary wedge pressure; QOL quality of life; VAS visual analog scale.Inte
rials o
vanta
that q
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r effica
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l meas
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June 16, 2009:2248–58 End Points in Acute Heart Failure Trialsegional differences in practice patterns. For example, LOS
or AHFS in European counties is approximately twice that
n the U.S. (20,21). Additionally, the increased use of “short
tay” holding units in emergency departments and the use of
ntravenous medications in heart failure clinics can con-
ound the definition of hospital stay.
Methods for quantifying the burden of hospital stay in
HFS have varied between studies. Traditional “time to
vent” analyses using Cox proportional hazards models,
hich have become standard in chronic heart failure trials,
ight be less relevant when the follow-up period is rela-
ively short (months rather than years). Time-to-event
ethods also censor patients after the initial event, thus
iscounting the clinical burden of multiple or prolonged
ospital stays. Additionally, the end point of “repeat hospi-
al stay” is paradoxically related to the LOS of the index
ospital stay, because patients with prolonged index hospital
tays have less time at risk for repeat hospital stay. Similarly,
ospital stay must be considered in the context of overall
ortality, because patients who do not survive are not at risk
or repeat hospital stay. A composite of death or heart
ailure hospital stay has been used as the co-primary end
oint for the recently completed EVEREST study and the
ngoing ASCEND-HF (Acute Study of Clinical Effective-
ess of Nesiritide in Decompensated Heart Failure) study
22,23).
Another approach that might more completely capture
he burden of mortality and hospital stay during the
ollow-up period is the end point of “days alive and out of
he hospital” (9,24). The theoretical advantage of this end
oint is that it combines mortality, LOS of the index
ospital stay, and the burden of subsequent hospital stays
nto a single end point. However, when index LOS is
specially long (which might be of particular concern in
tudies enrolling a majority of patients outside North
merica), it might lead to decreased power. Statistical
odeling performed for the purposes of designing the
SCEND-HF study suggests that, for interventions that
ake an impact on LOS for the index hospital stay, “days
live and out of hospital” end points have greater power than
he composite of death and repeat hospital stay. Conversely,
or interventions without an impact on initial LOS, the
omposite of death and repeat hospital stay is the more
owerful end point (23).
orsening heart failure/need for rescue therapy. Tradi-
ional end points for AHFS studies have tended to focus on
hort-term symptomatic status (discussed in detail in the
ollowing text) or post-discharge outcomes such as mortality
r repeat hospital stay. This dichotomy notably neglects a
ritical period of the AHFS episode, the time between
nitial stabilization (24 to 48 h) and eventual hospital
ischarge (Fig. 1). Recognition that commonly used end
oints do not reflect this important time period has led to
he development of “worsening heart failure” during therapy
s a novel outcome measure in AHFS. Although there is no
onsensus definition of worsening heart failure, typically it is iefined as either failure to improve (persistent signs and
ymptoms of heart failure despite therapy) or worsening
igns and symptoms of heart failure despite therapy. One
omponent of the worsening heart failure end point is the
equirement for “rescue therapy” (i.e., the need to initiate or
ntensify intravenous therapy [such as inotropes or intrave-
ous vasoactive agents] or implement mechanical cardiac or
entilatory support). Although the need for such rescue
herapy makes intuitive sense as part of an end point
esigned to capture lack of clinical improvement, guidance
rom European Medicines Agency (EMEA) suggests that
hey do not consider this an appropriate component of an
fficacy end point (25). Multiple recent trials have used
orsening heart failure end points as either a component of
he primary end point or an important secondary end point
26–28).
ymptom measures. Acute heart failure syndrome is a
ighly symptomatic disorder, and faster or more complete
esolution of symptoms is an important clinical goal for
HFS therapy. Patient-reported symptom measures have
ecome the most commonly used end points in AHFS
rials, either alone or in combination with others measures,
onsistent with the fundamental importance of helping
atients feel better or live longer.
Dyspnea has emerged as the current standard for patient-
eported clinical end point measures (29). Dyspnea is the
ost common presenting symptom for patients with
HFS, and hospital discharge is often dictated by resolu-
ion in dyspnea. Most contemporary phase III AHFS trials
ave used some measure of short-term changes in dyspnea
s a key end point (23,27,30) (Table 2).
Despite the apparent ascendance of dyspnea as a key
easure of efficacy in AHFS trials, there are significant
ssues regarding dyspnea as an end point. No validated
nstrument for dyspnea assessment currently exists that is
ccurate, reliable, reproducible between observers, and sen-
itive to important changes in dyspnea (31). This has led to
he use of an assortment of poorly validated instruments for
ssessing dyspnea, including Likert scales, visual analog
cales, and more complicated measures that incorporate
atient effort and time variables, such as the Baseline
yspnea Index (32) and Transient Dyspnea Index (33). In
prospective registry of patients with AHFS, patterns of
yspnea resolution were significantly affected by choice of
esponse instrument (34). Likert measures of dyspnea ini-
ially improved rapidly with no significant improvement
hereafter, whereas visual analog scale measurement of
yspnea improved continually throughout hospital stay.
ecently, a proposal for greater standardization of dyspnea
easurement in AHFS trials suggested sequential evalua-
ion of dyspnea with progressively greater provocation (lying
at, walking, and so forth) (31). Although intriguing, such
n instrument might be somewhat laborious to conduct, and
t requires further validation before it should be widely
mplemented.
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Table 2 Selected Large Phase 2 and 3 AHFS Trials and Their End Points
Study Acronym
(Ref. #)
Year of
Publication Intervention Primary End Point(s)
Key Secondary
End Points
Long-Term Clinical
Outcomes
VMAC (8) 2002 Nesiritide infusion 48 h
vs. nitroglycerine
infusion vs. placebo
Coprimary:
1. Change in PCWP at 3 h
2. Change in dyspnea (Likert) at 3 h
PCWP at 24 h, dyspnea at
24 and 48 h, global
clinical status
Tertiary end points:
48-h hypotension,
headaches; 30-day
mortality, myocardial
infarction, readmission,
and renal dysfunction;
6-month mortality (not
powered for definitive
analysis)
OPTIME (9) 2002 Milrinone infusion 48 h
vs. placebo
Cumulative days of hospital stay for
cardiovascular cause or days dead
within 60 days after randomization
Proportion of cases failing
therapy due to adverse
events or worsening
heart failure (sustained
SBP 80 mm Hg,
myocardial ischemia,
arrhythmias, persistent
CHF, inadequate
diuresis, organ
hypoperfusion), heart
failure score, global
health (VAS)
Primary end point
ESCAPE (24) 2005 Therapy guided by
pulmonary artery
catheter plus
clinical assessment
vs. clinical
assessment alone
Days alive and out of hospital during the
first 6 months
Adverse events related to
catheter use, 6-min
walk duration, QOL via
time trade-off, and
MLHF
Primary end point
VERITAS (27) 2007 Tezosentan infusion
24–72 h vs.
placebo
Co-primary:
1. Change in dyspnea (at 3, 6, and 24 h
with VAS 0–100) over 24 h (area
under the curve)
2. Death or worsening heart failure
(pulmonary edema, shock, new or
1 intravenous therapy, mechanical
cardiac or pulmonary support, renal
replacement therapy) at 7 days
Death or major
cardiovascular events
at 30 days; improved
hemodynamic
measures over 24 h;
LOS; days hospitalized
within 30 days;
6-month mortality
Secondary end points
SURVIVE (46) 2007 Levosimendan infusion
vs. dobutamine
infusion as long as
clinically indicated
in AHFS patients
requiring inotropic
support
All-cause mortality at 180 days All-cause mortality at
31 days; days alive or
out of hospital at 180
days; cardiovascular
mortality at 180 days;
change in BNP level at
24 h; dyspnea at 24 h;
patient-assessed global
assessment at 24 h
Primary and secondary
end points
REVIVE-2 (26) Not yet published
(presented
2005)
Levosimendan infusion
vs. placebo in
hemodynamically
stable AHFS
patients
Composite of clinical signs and
symptoms of heart failure over
5 days expressed as 3-stage end
point:
1. Better (moderately or markedly
improved global assessment at 6 h,
24 h, and 5 days with no worsening)
2. Same
3. Worse (death from any cause,
persistent or worsening heart failure
requiring intravenous diuretic agents,
vasodilators, or inotropes at any
time; or moderately or markedly
worse patient global assessment at
6 h, 24 h, or 5 days)
Change in BNP; mortality
at 90 days
Secondary end point
EVEREST (22,35) 2007 Tolvaptan vs. placebo
up to 112 weeks
Short-term composite: changes in global
clinical status (by VAS) and body
weight at day 7 or discharge
Long-term dual end points:
1. All-cause mortality (superiority and
noninferiority)
2. Cardiovascular death or heart failure
hospital stay (superiority only)
Composite components in
isolation at days 1 and
7 or discharge;
dyspnea at day 1;
peripheral edema at
day 7 or discharge;
KCCQ at 1 week and
6 months; body weight;
changes in serum
sodium
Main safety end point
ASCEND-HF (23) Enrolling Nesiritide infusion vs.
placebo
Coprimary:
1. Composite of all-cause mortality and
heart failure repeat hospital stay
through 30 days
2. Dyspnea at 6 and 24 h
Overall well-being (Likert)
6 and 24 h; days alive
and outside of hospital
within 30 days
Primary end pointContinued on next page
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June 16, 2009:2248–58 End Points in Acute Heart Failure TrialsPerhaps most problematic for the use of dyspnea as a
rimary end point is the possibility of relatively rapid
mprovement irrespective of therapy for AHFS. In the
lacebo arms of many recent AHFS studies, there was
ubstantial relief of dyspnea within 24 to 48 h with standard
herapy alone (27,30,35). More recently, studies that re-
uired a more objective measure of disease severity for
atient enrollment (such as natriuretic peptide levels) have
ot shown the same degree of dyspnea improvement in the
lacebo group, suggesting that more severely ill patients
ight have more unresolved dyspnea that could serve as a
arget for dyspnea-reducing therapy (28). In any case, for an
ncremental improvement in dyspnea to be considered a
ignificant therapeutic advance, it would need to be rela-
ively rapid, of substantial magnitude, and sustained beyond
he initial few hours of therapy.
Measures of patient-reported global health status, also
eferred to as general well-being, have also been incorpo-
ated into AHFS studies in a fashion similar to dyspnea
35). Global health status measures have the potential to
etter summarize the overall subjective state of being that a
atient is experiencing, thus capturing other domains of
HFS that might not be reflected by dyspnea measures.
he downside is a potential decrease in power due to
nclusion of symptoms that are not affected by the interven-
ion. In general, data suggest that measures of general
ell-being and those of dyspnea are highly concordant in
atients with AHFS, indicating that the choice of symptom
omain might not be critical (34).
urrogate End Points
surrogate end point is defined by the FDA as “a
aboratory measurement or physical sign that is used in
herapeutic trials as a substitute for a clinically meaningful
nd point that is a direct measure of how a patient feels,
unctions, or survives and is expected to predict the effect of
ontinued
Table 2 Continued
Study Acronym
(Ref. #)
Year of
Publication Intervention
PROTECT I and II (49) Enrolling Rolofylline infusion vs. placebo Com
1. B
2. S
3. W
SCEND-HF  Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure;
rtery Catheterization Effectiveness; EVEREST Efficacy of Vasopressin Antagonism in Heart Failu
xacerbations of Chronic Heart Failure; PROTECT Study of the Selective A1 Adenosine Receptor
reatment Effect on Congestion and Renal Function; REVIVE-2  Second Randomized Multicenter
atients with Acute Heart Failure in Need of Intravenous Inotropic Support; VERITAS  Value of E
anagement of Acute CHF; other abbreviations as in Table 1.he therapy” (36). To be valid, a surrogate end point should aeet clearly defined criteria: 1) the surrogate must be in the
ausal pathway from the intervention to the clinically
elevant outcome, as reflected by a strong association be-
ween the surrogate and the target; and 2) there must be no
mportant effects of the intervention on the outcome that
re not mediated through or captured by the surrogate (37).
ecause it is challenging to establish that these criteria are
et, surrogate measures are generally not accepted as proof
f efficacy but rather as a signal of effect. Currently, there are
o widely accepted surrogate end points in heart failure.
egulatory agencies have generally required that new ther-
pies address clinically relevant outcomes before approval.
ecent concerns about well-established surrogate end points
cholesterol and glucose reduction) support such a policy
38–40). Still, surrogate outcomes continue to have an
mportant role in the development of new therapies, because
hey often provide a more immediate manifestation of effect
nd typically allow for shorter and smaller trials in early
hase development. Consequently, early phase clinical stud-
es designed to provide “proof of concept” or to select dosing
or larger studies typically employ surrogate end points.
Unfortunately, the history of drug development in heart
ailure has been marked by the frequent failure of surrogate
nd points to accurately predict clinical outcomes in larger
fficacy trials. In the following text, we review possible
urrogate end points in the development of new AHFS
herapies.
emodynamic status. Until recently, changes in hemody-
amic status have been the primary focus of therapies for
HFS. Early trials of milrinone focused almost entirely on
ffects on filling pressures and cardiac output. In the VMAC
Vasodilation in the Management of Acute Congestive
eart Failure) study, post-capillary wedge pressure was 1 of
he 2 primary end points ultimately used for FDA approval
f nesiritide (8). Despite the hemodynamic benefits of
esiritide and milrinone, significant questions remained
rimary End Point(s)
Key Secondary
End Points
Long-Term Clinical
Outcomes
of clinical signs and
ms of heart failure over
expressed as 3-stage end
moderately or markedly
ed global assessment at
48 h with no worsening)
death from any cause,
ent or worsening heart failure
day 7, or creatinine
e 0.3 mg/dl at 7 and
s)
Safety; within trial costs Secondary end point
congestive heart failure; ESCAPE  Evaluation Study of Congestive Heart Failure and Pulmonary
ome Study with Tolvaptan; OPTIME Outcomes of a Prospective Trial of Intravenous Milrinone for
nist KW-3902 (rolofylline) for Patients Hospitalized With Acute HF and Volume Overload to Assess
tion of Intravenous Levosimendan Efficacy; SBP  systolic blood pressure; SURVIVE  Survival of
lin Receptor Inhibition with Tezosentan in Acute Heart Failure Study; VMAC  Vasodilation in theP
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sympto
7 days
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End Points in Acute Heart Failure Trials June 16, 2009:2248–58Additionally, hemodynamic parameters have not neces-
arily been successful in guiding dose selection in the
evelopment of new AHFS therapies. As an example, the
andomized Intravenous Tezosentan drug development
rogram studied the endothelin antagonist at doses of 50 to
00 mg/h, on the basis of the dose range that produced the
ost significant hemodynamic effect in early phase I drug
evelopment (41). Overall, this phase II program demon-
trated uncertain clinical benefit but a clear signal for greater
dverse events in the higher doses, suggesting that the dose
ange selected on the basis of maximizing hemodynamic
enefit was too high for a favorable risk-benefit ratio.
ubsequently, the phase III VERITAS (Value of Endothe-
in Receptor Inhibition with Tezosentan in Acute Heart
ailure Study) used a dose of 1 mg/h (27). Thus, despite
xtensive early phase hemodynamic studies, the “best dose”
f tezosentan remained unknown (at a50-fold range) well
nto phase III development.
luid balance/weight. Congestion is widely recognized as
laying a central role in the pathophysiology of AHFS, and
herapy aimed at reducing fluid congestion (primarily loop
iuretic agents) is prescribed to 90% of patients admitted for
HFS in the U.S. (42). Recently, a variety of new thera-
eutic approaches have been developed to address conges-
ion in AHFS, including vasopressin antagonists, adenosine
Hours Days
In-Hospital Rx
Time
Phase
Endpoints
∆ Dyspnea
∆ PGA
Worsening HF
Renal Dysfunction
Reh
Length of Stay
Mortality
∆ Hemodynamics/BNP
Cost-Effectiveness
Admission Discharge
Health Status / Q
Days Alive or Out of Hospital
Figure 1 AHFS Episode Timeline
Timeline showing that end points might represent different portions of the time co
and thus unique parts of the patient experience. BNP  B-type natriuretic peptide;ntagonists, and ultrafiltration. This has led to a substantial pnterest in the use of change in body weight as a potential
bjective surrogate end point reflecting decongestion. In the
argest trial of ultrafiltration, weight loss at 48 h was the
o-primary end point (along with dyspnea) (30). Similarly,
n the EVEREST trial the primary end point was a
omposite including changes in body weight (along with
atient-reported global clinical status) (35). In both of these
rials, it was the change in fluid status and not the symptom
easure that drove the difference in the composite primary
nd point. These findings suggest that the validity of change
n weight as a surrogate remains uncertain. Recent data
rom studies with implantable hemodynamic monitors have
uggested that the relationship between hemodynamic con-
estion, total body volume retention (reflected as weight
hange), and symptoms is more complex than previously
ppreciated (43).
iomarkers. The natriuretic peptides, which include
-type natriuretic peptide and its amino terminal fragment,
ave been established as important diagnostic tools in
HFS (44,45). Because of their association with heart
ailure disease severity and their wide clinical availability,
atriuretic peptide levels are attractive as potential surrogate
nd points. Because a primary driver of natriuretic peptide
evels is hemodynamic stress, many of the same concerns
hat apply to hemodynamic surrogates such as wedge
s Months
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June 16, 2009:2248–58 End Points in Acute Heart Failure Trialsatriuretic peptide levels are impacted by a variety of other
actors such as adrenergic tone, renin-angiotensin-
ldosterone activation, and ischemia, implying that natri-
retic peptide levels might be a more integrated measure of
he heart failure state than hemodynamic status.
In the SURVIVE (Survival of Patients with Acute Heart
ailure in Need of Intravenous Inotropic Support) and the
EVIVE-2 (Second Randomized Multicenter Evaluation
f Intravenous Levosimendan Efficacy) programs, decreases
n natriuretic peptide levels were assessed as important
econdary end points (26,46). In both studies, levosimendan
as associated with a substantial decrease in natriuretic
eptide levels compared with placebo (in REVIVE-2) and
obutamine (in SURVIVE). In REVIVE-2, this favorable
mpact of levosimendan on reducing natriuretic peptide
evels was associated with improvement in clinical symp-
oms and less worsening heart failure at 5 days but also
orresponded with an observed increase in adverse events
hypotension and arrhythmias) and a trend toward increased
ong-term mortality. In the SURVIVE study, levosimendan
id not result in improved short- or long-term clinical
utcomes compared with dobutamine, despite a reduction
n natriuretic peptide levels. At present, it remains unknown
hether a change in biomarker levels might play a role as a
urrogate end point for dose selection or proof of concept in
arly phase studies in AHFS.
enal function. The interaction between AHFS and the
idney has become a topic of substantially increased interest
n recent years (47). Worsening renal function during
ospital stay for AHFS, sometimes termed the “cardiorenal
yndrome,” has been shown to be a powerful predictor of
dverse outcomes in AHFS patients (48), and new therapies
uch as the adenosine antagonists have targeted preservation
f renal function as a therapeutic goal in AHFS. Thus,
lthough for many end points the distinction between a
linical end point and a surrogate is straightforward, mea-
ures of renal function seem to represent a grey zone
etween clinical end points, surrogate end points, and safety
nd points. In the ongoing rolofylline development pro-
ram, worsening renal function (defined as a change in
erum creatinine of 0.3 mg/dl) is a component of the
omposite primary end point (49). Although renal function
ould be considered a “safety end point,” a potentially useful
istinction can be made between demonstrating safety (i.e.,
howing that renal function is not worsened by a novel
herapy compared with control) and demonstrating efficacy
i.e., showing that renal function is preserved by the new
herapy compared with placebo).
afety End Points
iven the history of drug development in AHFS, the
verall safety profile of new AHFS therapies has become an
ssue of significant concern. In particular when the focus of
therapy is short-term symptom relief, establishing that this coes not occur at the expense of longer-term safety is
ritical. In this sense, safety end points are effectively
oninferiority measures, requiring specific statistical ap-
roaches in order to establish noninferiority with a pre-
pecified “equivalence boundary” (50). Evaluation of safety
or new therapies should be guided by an understanding of
he drug mechanism as well as by signals from earlier clinical
tudy (e.g., renal dysfunction with nesiritide, ischemia with
notropic agents). This requires testing specific safety hy-
otheses with the appropriate sample size that reasonably
alances the desire to limit the risk for potential post-
pproval adverse events with the need for efficient pathways
or evaluating new therapies (51). Additionally, planning of
hase III studies should include formal assessment of the
pper boundary of risk (either relative or absolute) that can
e excluded by the planned sample size. Although appro-
riately planned phase III safety evaluation is invaluable,
hase IV safety surveillance remains critical, because even
ith large sample sizes rare but clinically relevant increases
n severe adverse events might not be fully excluded. For
xample, despite a sample size of 7,000 patients, the
ngoing ASCEND-HF study is powered to detect (with
5% confidence and 90% power) a hazard ratio of 1.47 for
0-day mortality (assuming a baseline 30-day mortality rate
f 4%). Ultimately, the degree of risk that must be “ruled
ut” to declare a treatment “safe” should be related to the
egree and type of benefit (i.e., a drug that improves
hort-term symptoms only might be held to a higher
tandard of safety than 1 with more substantive clinical
enefits).
ultiple and Composite End Points:
utting it Together
here is no single end point that accurately captures the
otality of the patient experience with AHFS. Thus,
ubstantial interest exists for combining end points in
rder to measure the impact of interventions on the
arious domains of possible benefit. One method for
ddressing these issues is the use of multiple primary end
oints. Using more than 1 primary end point requires
ppropriate adjustment for multiple statistical compari-
ons. Typically, this takes the form of allocating the alpha
i.e., the potential for type I error) among the various end
oints. For example, in the ongoing ASCEND-HF study
f nesiritide, the alpha is allocated between the co-
rimary end points of 1) death or heart failure hospital
tay at 30 days (alpha  0.045); and 2) dyspnea assess-
ent at 6 and 24 h (alpha  0.005) (23).
Distinct from the use of multiple primary end points,
omposite end points attempt to combine the various aspects
f the AHFS syndrome into a single integrated measure. In
heir simplest form, a composite end point simply combines 2
eparate “events” into 1 category (e.g., cardiovascular death or
eart failure repeat hospital stay). Statistically, the use of
omposites increases the total event rate and therefore might
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End Points in Acute Heart Failure Trials June 16, 2009:2248–58ncrease statistical power. Importantly, however, composite
nd points only increase statistical power if the intervention has
n effect on multiple aspects of the composite. The inclusion of
actors in the composite end point that are not impacted by the
ntervention might actually “dilute” the observed treatment
ffect and decrease the overall statistical power (52).
A variety of complex composites have been proposed
hat try to incorporate many aspects of the patient
xperience into a single end point. In the REVIVE-2
tudy of levosimendan, the primary end point was the
lassification of the patient as “better, the same, or worse”
ith a pre-specified definition that included symptoms,
orsening heart failure events, and death over a 5-day
eriod (26) (Table 2). Patients with improved symptoms
moderate or marked improvement at 6 h, 24 h, and 5
ays) and no worsening were classified as improved,
hereas patients dying, experiencing worsening heart
ailure requiring rescue therapy, or experiencing worsen-
ng symptoms were classified as worse. Patients classified
s neither better nor worse were classified as unchanged.
otably, the REVIVE trials demonstrated improvement
n this end point (p  0.015), but levosimendan was not
pproved in the U.S. due to concerns about hypotension
nd a possible trend toward late mortality in the levosi-
endan group. The ongoing phase III PROTECT I and
I (Study of the Selective A1 Adenosine Receptor An-
agonist KW-3902 [rolofylline] for Patients Hospitalized
ith Acute HF and Volume Overload to Assess Treat-
ent Effect on Congestion and Renal Function) trial
ses a similar “trichotomous” end point that incorporates
ymptom relief, worsening heart failure and/or renal
unction, and mortality (28).
Another alternative to these composite end points is
ierarchical end points based on ranking of events,
ometimes termed the “global rank approach.” In this
ype of scheme, all patients participating in a clinical trial
re ranked on the basis of a pre-specified hierarchy of
vents. For example, time to death would be ranked at
he bottom, then repeat hospital stay for heart failure,
nd so forth. Patients not experiencing any of these hard
vents could be ranked on the basis of a continuous
easure (e.g., change in a symptom measure or a surro-
ate such as natriuretic peptides). The primary analysis in
his type of analysis is the nonparametric comparison of
he ranks between those patients in the intervention
roup versus those in the control group. One advantage
f this type of end point is that it “weighs” the compo-
ents of the clinical experience in a way that is generally
ongruent with clinical judgment and patient-perceived
orth (mortality most important, nonfatal events next,
ymptoms next, and so on). The advantages and disad-
antages of this type of global rank end point for trials of
echanical cardiac support devices have been reviewed inetail (53).egulatory Issues
egulatory requirements for approval of new drugs for
HFS have evolved rapidly over the past decade in response
o many of the AHFS trial failures outlined in the preceding
ext. Currently, harmonization of regulatory agencies is
acking, often resulting in AHFS studies with multiple
rimary end points designed to meet divergent regulatory
equirements. For example, the EMEA has neither em-
raced repeat hospital stay as an important end point in
HFS nor accepted composite end points. Therefore,
pproval requires either improvement in a symptom-based
nd point or mortality. By limiting the end points of a
linical trial to these opposite ends of the spectrum, the
efault has often been a symptom-based end point. In
ontrast, the FDA has been willing to accept composite end
oints and has encouraged some form of safety evaluation.
his lack of regulatory harmonization has encouraged the
se of co-primary end points and overly complex trial
esigns in order to meet divergent regulatory requirements
22,23).
ey Considerations for Future End Point Design
he historical perspective gained by reviewing recent AHFS
rials helps define general principles to guide future AHFS
nd point selection (Table 3). First and foremost, phase III
rials of AHFS therapies must focus on measures of clinical
mportance assessed over a reasonable duration (54). Post-
ischarge clinical events such as mortality and major non-
atal events (such as repeat hospital stay) are of unequivocal
linical importance, and reducing these events is a major
nmet clinical need in AHFS patients. Thus, treatments
esigned to improve these outcomes should be a primary
oal of therapeutic development in AHFS. As noted earlier,
hether traditional time-to-event analysis or alternate strat-
gies for capturing these events (e.g., days alive and out of
ospital) are preferable might differ depending on the
ature of the intervention being tested, but the general
rinciple remains the same. Substantial clinical changes
uring the index hospital stay (such as worsening heart
ailure and/or the need for rescue therapy) also capture an
mportant element of the clinical course and are valid for
easuring the clinical benefits of therapy, so long as they are
ccompanied by longer-term evidence of safety. Although
ey Considerations for an Idealcute Heart Fa lure Syndromes End Point
Table 3 Key Considerations for an IdealAcute Heart Failure Syndromes End Point
1. Measure something of clinical value (i.e., relates to patients feeling better
and/or living longer or saves resources)
2. Assess over a reasonable time period (i.e., more than 24 h)
3. Validate measurement tools (e.g., symptom scales)
4. Account for the relative value of each component in composites
(i.e., ranking methods)
5. Standardize key end points between trials
6. Harmonize regulatory agency expectations (i.e., Food and Drug
Administration and European Medicines Agency)
s
s
b
t
t
c
t
t
s
e
f
e
r
p
s
p
u
p
e
b
m
c
w
m
C
T
o
p
d
c
c
e
r
l
t
t
p
p
d
b
e
R
d
6
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2257JACC Vol. 53, No. 24, 2009 Allen et al.
June 16, 2009:2248–58 End Points in Acute Heart Failure Trialsymptom relief remains an important goal of therapy,
ymptomatic improvement (in the absence of other clinical
enefits) must be rapid, substantial, and sustained beyond
he initial hours of treatment to be considered a significant
herapeutic advance over usual care. Dyspnea relief is best
onsidered in the context of other short- and intermediate-
erm benefits, suggesting that composite end points such as
hose from REVIVE-2 and the PROTECT program are
uperior to isolated dyspnea measures in demonstrating
fficacy (26,49). Finally, safety remains a critical challenge
or evaluating new AHFS therapies. Given the size of
xperience needed to provide definitive evidence of safety,
egulatory agencies should consider providing initial ap-
roval but with specific requirements for post-marketing
afety surveillance with valid safety end points and appro-
riate studies to judge the relative risks of therapeutic versus
sual care.
Moving forward, standardization and validation of end
oint measures is critical. The call for a common dyspnea
nd point that is objective and then validated is a beginning,
ut such efforts should extend to other AHFS end point
easures. Greater agreement and harmonization between
linical trialists, industry sponsors, and regulatory agencies
ill also be required in order to evaluate new therapies in the
ost efficient way possible.
onclusions
he field of AHFS trial design continues to evolve. Reliance
n short-term hemodynamic benefits or other surrogate end
oints is clearly unacceptable as a means of establishing
efinitive clinical efficacy. Moving forward, phase III clini-
al trials in AHFS will need to focus on measures that
learly reflect clinical efficacy (mortality, hospital stay, wors-
ning heart failure, and/or clinically meaningful and durable
elief of symptoms) as well as provide definitive evidence of
onger-term safety. This will almost certainly require larger
rials than those previously used to evaluate new AHFS
herapies (thousands of patients rather than hundreds of
atients). Studies such as ASCEND-HF can establish a
recedent for doing trials adequately powered to provide
efinitive evidence regarding both efficacy and safety and
ring the field of AHFS firmly into the mainstream of
vidence-based medicine.
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